Forte Biosciences: Key Outcomes from 2024 Stockholders Meeting
Company Announcements

Forte Biosciences: Key Outcomes from 2024 Stockholders Meeting

The latest update is out from Forte Biosciences (FBRX).

Forte Biosciences, Inc. successfully conducted its 2024 annual stockholders meeting, resulting in the election of Class I directors and the ratification of KPMG LLP as the independent accounting firm for the upcoming fiscal year. Additionally, stockholders approved an amended Equity Incentive Plan and a reverse stock split of not less than 1-for-5 and not more than 1-for-30. The board finalized the reverse stock split at a 1-for-25 ratio, to be effective from August 28, 2024, with proportional adjustments to outstanding equity awards and future issuance plans. No fractional shares will be issued, with stockholders receiving cash compensation instead.

For a thorough assessment of FBRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
Christine BrownFBRX Upcoming Earnings Report: What to Expect?
TipRanks Auto-Generated NewsdeskForte Biosciences Welcomes New Directors Amidst Strategic Changes
TheFlyForte Biosciences trading halted, news pending
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App